Infinium Pharmachem Ltd
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]
- Market Cap ₹ 310 Cr.
- Current Price ₹ 222
- High / Low ₹ 316 / 130
- Stock P/E 27.4
- Book Value ₹ 42.2
- Dividend Yield 0.00 %
- ROCE 32.8 %
- ROE 50.1 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 53.3%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
39 | 71 | 99 | 114 | 136 | |
36 | 66 | 89 | 98 | 117 | |
Operating Profit | 2 | 5 | 10 | 16 | 19 |
OPM % | 6% | 7% | 10% | 14% | 14% |
1 | 1 | 1 | 1 | 2 | |
Interest | 1 | 1 | 2 | 3 | 2 |
Depreciation | 1 | 1 | 1 | 1 | 3 |
Profit before tax | 1 | 4 | 9 | 13 | 15 |
Tax % | 30% | 28% | 23% | 24% | 24% |
1 | 3 | 7 | 10 | 12 | |
EPS in Rs | 4.65 | 13.60 | 30.55 | 9.30 | 8.12 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 24% |
TTM: | 19% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 61% |
TTM: | 19% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 51% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 53% |
Last Year: | 50% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | 1 | 1 | 1 | 5 | 14 |
Reserves | 3 | 6 | 12 | 17 | 45 |
9 | 11 | 23 | 29 | 0 | |
9 | 17 | 23 | 19 | 27 | |
Total Liabilities | 22 | 34 | 59 | 71 | 85 |
4 | 5 | 4 | 19 | 20 | |
CWIP | 0 | 4 | 8 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 |
18 | 26 | 46 | 52 | 66 | |
Total Assets | 22 | 34 | 59 | 71 | 85 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
3 | 7 | 12 | 9 | -13 | |
-1 | -5 | -7 | -5 | -4 | |
-1 | -1 | -2 | -3 | 23 | |
Net Cash Flow | 1 | 1 | 3 | 1 | 6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 75 | 59 | 57 | 49 | |
Inventory Days | 84 | 62 | 78 | 89 | |
Days Payable | 82 | 79 | 56 | 31 | |
Cash Conversion Cycle | 76 | 43 | 78 | 108 | |
Working Capital Days | 76 | 36 | 58 | 89 | |
ROCE % | 32% | 38% | 36% |
Documents
Announcements
-
Press Release
2 July 2024 - Infinium Pharmachem Limited has informed regarding a press release dated July 02, 2024, titled "Infinium Pharmachem Ltd CommencesConstruction of New Project for manufacturing Contrast Media …
-
Corrigendum
25 June 2024 - Infinium Pharmachem Limited has informed regarding Corrigendum to Notice of Extra Ordinary General Meeting to be held on July 06, 2024
-
Analysts/Institutional Investor Meet/Con. Call Updates
15 June 2024 - Infinium Pharmachem Limited has informed about Transcript
-
Notice Of Shareholders Meetings-XBRL
11 June 2024 - INFINIUM PHARMACHEM LIMITED has informed about Notice of Shareholders Meeting for Extra-ordinary Meeting to be held on 06-Jul-2024
-
Shareholders meeting
11 June 2024 - Infinium Pharmachem Limited has informed regarding Notice of Extraordinary General Meeting to be held on July 06, 2024
Annual reports
Concalls
-
Jun 2024Transcript PPT REC
-
Mar 2024Transcript PPT
Business Overview:[1]
IPL is a GMP compliant, FDA Approved and ISO 9001-2015 certified coimpany which does development, manufacture, and export of Iodine Derivatives & API. Currently, it has 250+ intermediates and 15+ APIs. It supplies a range of Iodine derivatives on Order to Made basis